StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

Immunocore r&d expenses

Research and development expenses are spending on new products and technology.

Immunocore's R&D Expenses for the twelve months ending Jun 30, 2026 was $284.45M, up 19.0% year over year. For fiscal 2025 it was $274.87M, up 23.7% from the year before. The highest annual figure on record is $274.87M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$274.87M+23.7%
FY2024Dec 31, 2024$222.15M+35.8%
FY2023Dec 31, 2023$163.55M+60.5%
FY2022Dec 31, 2022$101.92M+1.7%
FY2021Dec 31, 2021$100.25M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$73.95M+7.2%
Q1 FY2026Mar 31, 2026$61.11M+8.2%
Q4 FY2025Dec 31, 2025$78.82M+29.5%
Q3 FY2025Sep 30, 2025$70.57M+33.7%
Q2 FY2025Jun 30, 2025$69.01M+35.1%
Q1 FY2025Mar 31, 2025$56.47M-1.7%
Q4 FY2024Dec 31, 2024$60.85M+33.5%
Q3 FY2024Sep 30, 2024$52.77M+22.0%
Q2 FY2024Jun 30, 2024$51.07M+33.8%
Q1 FY2024Mar 31, 2024$57.46M+57.1%
Q4 FY2023Dec 31, 2023$45.57M–
Q3 FY2023Sep 30, 2023$43.25M–
Q2 FY2023Jun 30, 2023$38.16M–
Q1 FY2023Mar 31, 2023$36.57M–

More Immunocore figures

See a number that looks wrong?